Von Willebrand Factor Concentrate During ECMO Support
Status:
Active, not recruiting
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
During treatments with extracorporeal circuits such as extracorporeal membrane oxygenation
(ECMO) degradation of high molecular weight (HMW) of von Willebrand factor (vWF) multimers
occur leading to an acquired von Willebrand disease. This disease is associated with
increased bleeding and requirement for the transfusion with allogenic blood products
especially packed red blood cells (PRBCs). A continuous treatment with von Willebrand factor
concentrate (vWFC) may restore the multimers and bleeding can be avoided. Therefore a
randomized, double-blind, prospective, controlled, two-arm clinical trial was designed,
comparing patients receiving vWFC versus placebo.